Polymeric Micelles

Gaal, Ethlinn V.B. van; Crommelin, Daan J.A.

doi:10.1007/978-3-319-16241-6_2

Cited by 4 publications

(5 citation statements)

References 220 publications

(292 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, despite the biocompatibility of the human albumin protein it contains, this formulation has only moderately increased the bioavailability and safety of PTX because it continues to cause side effects such as hair loss, weakness, decreases in the red blood cell count and joint and muscle pain (Thomas et al., 2015). In addition to Abraxane, paclitaxel is also marketed on two other nanoplatforms for parenteral administration, liposomes (Lipusu®) and polymeric micelles, namely Genexol®PM (Ye et al., 2013), Nanoxel® (Kim et al., 2001) and Paclical® (van Gaal and Crommelin, 2015). In the last decade, other types of nanoencapsulation have been performed in order to modulate the biopharmaceutical properties of PTX and various systems are under investigation at the moment (Cosco et al., 2011; Thomas et al., 2015).…”

Section: Introductionmentioning

confidence: 99%

Paclitaxel-loaded sodium deoxycholate-stabilized zein nanoparticles: characterization and in vitro cytotoxicity

Gagliardi

Bonacci

Paolino

et al. 2019

Heliyon

View full text Add to dashboard Cite

Paclitaxel (PTX) is one of the most successful antineoplastic drugs and is widely used for the treatment of many forms of advanced and refractory cancer. Unfortunately, various drawbacks including non-selective cytotoxicity, poor water solubility and low bioavailability limit its clinical use. The aim of this study was to characterize a novel colloidal system made up of the natural protein zein, that would be able to efficiently retain the anticancer compound and increase its in vitro pharmacological effects. In fact, zein has promising characteristics that render it a potential material to be used in drug delivery application. The influences of temperature, pH and serum incubation on the stability of these particles, entrapment efficiency of PTX and in vitro toxicity on different cancer cell lines were evaluated. The nanosystems containing PTX demonstrated suitable storage stability, and were not destabilized by temperatures of up to 50 °C, pH alterations, the freeze-drying process or serum proteins. The encapsulation of PTX did not destabilize the structure of the zein nanoparticles and a suitable drug entrapment efficiency resulted. PTX-loaded zein nanoparticles showed an increased toxicity on different cancer cell lines with respect to the free drug, confirming its potential application in preclinical and clinical investigations.

show abstract

Section: Introductionmentioning

confidence: 99%

Paclitaxel-loaded sodium deoxycholate-stabilized zein nanoparticles: characterization and in vitro cytotoxicity

Gagliardi

Bonacci

Paolino

et al. 2019

Heliyon

View full text Add to dashboard Cite

show abstract

“…On the basis of the lack of infusion-related reactions and initial signs of efficacy, NK911 moved into a Phase II clinical trial. The results of this study have yet to be reported, and the latest publicly available updates are several years old. , …”

Section: Block Copolymer Micelle-based Drug Formulations In Clinical ...mentioning

confidence: 97%

“…It was approved exclusively in South Korea for patients with MBC, NSCLC, and ovarian cancer. Cynviloq is now on the market in India, the Philippines, and Vietnam for treatment of patients with MBC and metastatic NSCLC and is currently making its way through clinical trials in many countries, including a Phase IV trial in South Korea for MBC . The BCMs in Cynviloq are formed from the copolymer methoxy-PEG- b -poly( d,l -lactide) (mPEG- b -PDLLA) (2000:1750 g/mol) using the solid dispersion method .…”

Section: Block Copolymer Micelle-based Drug Formulations In Clinical ...mentioning

confidence: 99%

“…However, Paxceed entered clinical trials for a number of nononcology indications, including psoriasis (NCT00006276), rheumatoid arthritis (NCT00055133), and multiple sclerosis. However, since 2004, no updates have been provided on clinical evaluation of Paxceed …”

Section: Block Copolymer Micelle-based Drug Formulations In Clinical ...mentioning

confidence: 99%

“…Block copolymer micelles (BCMs) encapsulating anticancer agents were first developed in the late 1980s and since then have gained widespread interest as a viable drug delivery platform. During the past three decades, intense preclinical research on this nanoplatform has enabled a number of promising BCM formulations to enter clinical development, with two receiving regulatory approval (Cynviloq and Nanoxel). − …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Overcoming the Road Blocks: Advancement of Block Copolymer Micelles for Cancer Therapy in the Clinic

2017

View full text Add to dashboard Cite

With countless preclinical studies on block copolymer micelles (BCMs) successfully demonstrating the superiority of these advanced drug delivery formulations over conventional formulations, it remains somehow discouraging that only a few have reached clinical evaluation and practice. With a critical eye, this review aims to compare and summarize the preclinical and clinical data available on several BCM formulations and to identify their primary role in drug delivery as "carrier" or "solubilizer". This review focuses on polymeric micelles that have reached clinical evaluation and/or are being pursued commercially. Where available, we aim to compare the pharmacokinetics, toxicity, and efficacy data obtained in preclinical studies to identify the factors that likely played a key role in a decision to move these formulations forward from the bench to a first-in-human trial. Finally, we summarize clinical data obtained to date, where available, and conclude with the impact that each formulation has had on patients in terms of safety and efficacy.

show abstract